Hemab Therapeutics (NASDAQ:COAG) Releases Earnings Results, Misses Expectations By $0.07 EPS

Hemab Therapeutics (NASDAQ:COAG) announced its quarterly earnings results on Tuesday. The company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.07), FiscalAI reports.

Here are the key takeaways from Hemab Therapeutics’ conference call:

• Hemab initiated SOLARA, its pivotal Phase III trial of sutacimig in Glanzmann thrombasthenia, with about 75 participants and a single-arm design comparing bleed rates before and during treatment. The FDA recommended considering a randomized trial; Hemab says it believes the chosen design is appropriate, but the agency’s feedback leaves regulatory uncertainty.
• Hemab highlighted Phase II extension results for sutacimig in Glanzmann, including fewer treated bleeds for 92% of participants who bled during run-in and a 62% reduction in mean high-intensity treated bleed rate. The company also reported three grade 2 thromboembolic events in higher-exposure cohorts and/or participants with multiple risk factors; it selected a lower weekly dose for SOLARA.
• HMB-002 showed proof of mechanism in von Willebrand disease, with peak increases of about 2.5-fold in von Willebrand factor and factor VIII and durability that may support monthly dosing. Hemab said eight of nine evaluable patients had no treated bleeds in the 28 days after dosing, but noted the early observations were descriptive and the study was not designed to measure efficacy.
• Sutacimig’s early Factor VII deficiency data showed a greater-than-50% shortening of prolonged prothrombin time in two participants, with exposure maintained through day 22; updated data are expected at ASH. Hemab also began a Phase I trial of HMB-003 and reported preclinical monkey data showing a shift toward less severe menstrual bleeding, with initial human data expected in mid-2027.
• Hemab reported $430.2 million in cash, equivalents and marketable securities at September 30, and expects its cash to fund operations into 2029. Quarterly R&D and G&A expenses rose year over year as clinical programs advanced and personnel costs increased.

Hemab Therapeutics Stock Performance

COAG traded down $0.63 on Wednesday, hitting $38.14. 160,939 shares of the company’s stock were exchanged, compared to its average volume of 396,710. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $55.42. The company has a market capitalization of $1.78 billion and a PE ratio of -1.54. The firm’s 50-day simple moving average is $37.32.

Wall Street Analyst Weigh In

COAG has been the topic of a number of recent analyst reports. Wedbush increased their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 12th. Weiss Ratings cut Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 25th. Rodman & Renshaw began coverage on Hemab Therapeutics in a research report on Monday, October 12th. They issued a “buy” rating and a $56.00 price objective for the company. JPMorgan Chase & Co. started coverage on Hemab Therapeutics in a research note on Thursday, October 15th. They set an “overweight” rating and a $70.00 target price for the company. Finally, Lifesci Capital started coverage on Hemab Therapeutics in a research report on Monday. They set an “outperform” rating and a $65.00 target price on the stock. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Institutional Investors Weigh In On Hemab Therapeutics

A number of hedge funds have recently modified their holdings of COAG. Russell Investments Group Ltd. acquired a new position in Hemab Therapeutics during the third quarter worth about $46,000. China Universal Asset Management Co. Ltd. grew its stake in Hemab Therapeutics by 77.8% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 6,400 shares of the company’s stock valued at $209,000 after acquiring an additional 2,800 shares in the last quarter. Squarepoint Ops LLC acquired a new stake in Hemab Therapeutics in the 2nd quarter valued at about $230,000. Profund Advisors LLC purchased a new position in Hemab Therapeutics in the 3rd quarter worth approximately $246,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of Hemab Therapeutics during the 2nd quarter worth approximately $688,000.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company developing treatments for serious bleeding and thrombotic disorders, with a focus on conditions that have limited treatment options. Its research centers on therapies intended to help restore or regulate blood clotting. The company’s lead candidate, HMB-001, is an investigational bispecific antibody being developed for Glanzmann thrombasthenia, a rare inherited bleeding disorder. Hemab is also advancing research into additional disorders affecting hemostasis, the process that helps the body control bleeding.